Literature DB >> 27034397

Murine Tumor Models for Oncolytic Rhabdo-Virotherapy.

Theresa Falls1, Dominic Guy Roy1, John Cameron Bell1, Marie-Claude Bourgeois-Daigneault1.   

Abstract

The preclinical optimization and validation of novel treatments for cancer therapy requires the use of laboratory animals. Although in vitro experiments using tumor cell lines and ex vivo treatment of patient tumor samples provide a remarkable first-line tool for the initial study of tumoricidal potential, tumor-bearing animals remain the primary option to study delivery, efficacy, and safety of therapies in the context of a complete tumor microenvironment and functional immune system. In this review, we will describe the use of murine tumor models for oncolytic virotherapy using vesicular stomatitis virus. We will discuss studies using immunocompetent and immunodeficient models with respect to toxicity and therapeutic treatments, as well as the various techniques and tools available to study cancer therapy with Rhabdoviruses.
© The Author 2016. Published by Oxford University Press on behalf of the Institute for Laboratory Animal Research. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  biotherapeutic; cancer; efficacy; murine model; oncolytic virus; treatment; tumor; vesicular stomatitis virus (VSV)

Mesh:

Year:  2016        PMID: 27034397      PMCID: PMC4816122          DOI: 10.1093/ilar/ilv048

Source DB:  PubMed          Journal:  ILAR J        ISSN: 1084-2020


  163 in total

1.  Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses.

Authors:  Karishma Rajani; Christopher Parrish; Timothy Kottke; Jill Thompson; Shane Zaidi; Liz Ilett; Kevin G Shim; Rosa-Maria Diaz; Hardev Pandha; Kevin Harrington; Matt Coffey; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

2.  Increased initiation and growth of tumor cell lines, cancer stem cells and biopsy material in mice using basement membrane matrix protein (Cultrex or Matrigel) co-injection.

Authors:  Rafael Fridman; Gabriel Benton; Irina Aranoutova; Hynda K Kleinman; R Daniel Bonfil
Journal:  Nat Protoc       Date:  2012-05-17       Impact factor: 13.491

3.  Enhanced oncolytic activity of vesicular stomatitis virus encoding SV5-F protein against prostate cancer.

Authors:  Guimin Chang; Shuping Xu; Makiko Watanabe; Himangi R Jayakar; Michael A Whitt; Jeffrey R Gingrich
Journal:  J Urol       Date:  2010-02-20       Impact factor: 7.450

4.  Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.

Authors:  Amy K LeBlanc; Shruthi Naik; Gina D Galyon; Nathan Jenks; Mike Steele; Kah-Whye Peng; Mark J Federspiel; Robert Donnell; Stephen J Russell
Journal:  Hum Gene Ther Clin Dev       Date:  2013-12       Impact factor: 5.032

5.  Pancreatic stellate cells: partners in crime with pancreatic cancer cells.

Authors:  Alain Vonlaufen; Swapna Joshi; Changfa Qu; Phoebe A Phillips; Zhihong Xu; Nicole R Parker; Cheryl S Toi; Romano C Pirola; Jeremy S Wilson; David Goldstein; Minoti V Apte
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 6.  Cell carriers for oncolytic viruses: Fed Ex for cancer therapy.

Authors:  Candice Willmon; Kevin Harrington; Timothy Kottke; Robin Prestwich; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2009-08-18       Impact factor: 11.454

7.  Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus.

Authors:  Maryam Moussavi; Howard Tearle; Ladan Fazli; John C Bell; William Jia; Paul S Rennie
Journal:  Mol Ther       Date:  2013-01-22       Impact factor: 11.454

8.  Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Authors:  Diana M Rommelfanger; Phonphimon Wongthida; Rosa M Diaz; Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Richard G Vile
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

9.  Systemic delivery of oncolytic viruses: hopes and hurdles.

Authors:  Mark S Ferguson; Nicholas R Lemoine; Yaohe Wang
Journal:  Adv Virol       Date:  2012-01-31

10.  Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy.

Authors:  Alexander Muik; Catherine Dold; Yvonne Geiß; Andreas Volk; Marina Werbizki; Ursula Dietrich; Dorothee von Laer
Journal:  J Mol Med (Berl)       Date:  2012-08       Impact factor: 4.599

View more
  5 in total

1.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

2.  Pathology Principles and Practices for Analysis of Animal Models.

Authors:  Sue E Knoblaugh; Tobias M Hohl; Krista M D La Perle
Journal:  ILAR J       Date:  2018-12-01

Review 3.  Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.

Authors:  Amelia Sadie Aitken; Dominic Guy Roy; Marie-Claude Bourgeois-Daigneault
Journal:  Biomedicines       Date:  2017-01-04

4.  The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer.

Authors:  Liesa-Marie Schreiber; Carles Urbiola; Krishna Das; Bart Spiesschaert; Janine Kimpel; Fabian Heinemann; Birgit Stierstorfer; Philipp Müller; Monika Petersson; Patrik Erlmann; Dorothee von Laer; Guido Wollmann
Journal:  Br J Cancer       Date:  2019-09-18       Impact factor: 7.640

5.  Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment.

Authors:  Marie-Claude Bourgeois-Daigneault; Lauren Elizabeth St-Germain; Dominic Guy Roy; Adrian Pelin; Amelia Sadie Aitken; Rozanne Arulanandam; Theresa Falls; Vanessa Garcia; Jean-Simon Diallo; John Cameron Bell
Journal:  Breast Cancer Res       Date:  2016-08-08       Impact factor: 6.466

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.